- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
New Head-to-Head Phase 3 Study Data Show Ponesimod Superiority Versus Aubagio® (teriflunomide) 14 mg in Adults with Relapsing Multiple Sclerosis (MS)
OPTIMUM Phase 3 study data presented for the first time during oral presentation at the 35th Congress of The European Committee for Treatment and Research in Multiple Sclerosis
New Data from Esketamine Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
Global clinical program is the first to study this severely ill patient population, who are typically excluded from antidepressant treatment studies